EPM in Horses: Causes, Symptoms, Diagnosis, and Treatment

Your horse stumbles on the flat. Then you notice one hip looks oddly wasted compared to the other. The farrier mentions the horse is dragging a hind toe. None of these signs alone screams emergency, but together they paint a picture that should put EPM on your radar immediately. Equine Protozoal Myeloencephalitis is one of those diseases that creeps in slowly, mimicking lameness or poor coordination, and by the time it becomes obvious, significant neurological damage may already be underway.

What Causes EPM? The Sarcocystis neurona Lifecycle

The primary culprit behind EPM is Sarcocystis neurona, a single-celled protozoal parasite with a lifecycle that reads like something out of a parasitology textbook's most convoluted chapter. The Virginia opossum (Didelphis virginiana) serves as the definitive host, meaning the parasite completes its sexual reproductive cycle within the opossum's intestinal tract. Sporocysts are then shed in opossum feces, contaminating pastures, feed bins, water troughs, and hay storage areas.

Here's where horses enter the picture, and it's entirely accidental. Horses are aberrant, dead-end hosts. They were never meant to be part of this lifecycle at all. When a horse ingests sporocysts from contaminated feed or water, the parasites cross the intestinal wall, enter the bloodstream, and eventually penetrate the blood-brain barrier to invade the central nervous system. Once inside the spinal cord and brain, the protozoa cause inflammation and direct cellular damage to neural tissue.

A second, less common organism, Neospora hughesi, can also cause EPM, though it accounts for a much smaller percentage of cases. The transmission route for N. hughesi remains less clearly defined.

The geographic range of the Virginia opossum essentially maps the risk zone for EPM. Horses in the eastern United States, the Midwest, and increasingly the Pacific Northwest face the highest exposure. Seroprevalence studies show that up to 50-60% of horses in endemic areas have antibodies against S. neurona, meaning they've been exposed. But here's the critical distinction: exposure does not equal disease. Only a small fraction of exposed horses, roughly 1% or less, actually develop clinical EPM.

Why Some Horses Get Sick and Others Don't

If half the horses in some regions test seropositive, why do so few develop neurological disease? The answer sits squarely with the immune system. Horses that develop clinical EPM almost always have some form of immune compromise, whether from stress, transport, heavy training, concurrent illness, age extremes, or corticosteroid use.

Stress is the big one. A horse shipped across the country to a new barn, a mare going through a difficult foaling, a young horse pushed hard in early training. These scenarios create windows of immune vulnerability where the parasite gains a foothold in neural tissue that a robust immune response would normally prevent.

Some researchers have also investigated genetic predisposition, looking at variations in equine major histocompatibility complex (MHC) genes that might make certain horses less capable of mounting an effective immune response against the protozoa. This work is still evolving, but it may explain why some farms see repeated cases in related horses.

Recognizing EPM Symptoms: The Asymmetry Problem

EPM is a master of disguise. Its symptoms overlap with dozens of other conditions, from wobbler syndrome to West Nile virus to simple lameness. But there's one hallmark feature that should make your ears perk up: asymmetry.

Unlike many neurological conditions that affect both sides of the body equally, EPM tends to produce asymmetric signs. You might see:

• Ataxia (incoordination) that's worse on one side than the other
• Focal muscle atrophy, where one gluteal or one shoulder wastes away while the opposite side remains normal
• Abnormal gait with circumduction, toe dragging, or interference, sometimes only in one limb
• Head tilt or facial nerve paralysis if the brainstem is involved
• Difficulty swallowing in cases affecting cranial nerves
• Behavioral changes including depression, head pressing, or altered mentation

The neurological exam will often reveal deficits that don't fit a neat bilateral pattern. A horse might be grade 3 ataxic in the right hind but only grade 1 in the left. The tail might pull easily to one side but resist normally on the other. This patchwork of deficits reflects where the protozoa have set up shop within the CNS, which is essentially random.

Symptom progression varies wildly. Some horses decline over weeks, others over months. Rare acute cases can present with sudden recumbency, though this is the exception. If your horse is showing any combination of incoordination, stumbling, or unexplained muscle loss, particularly if it appears uneven, get your veterinarian involved for a proper lameness and neurological evaluation.

Diagnosing EPM: Blood Tests Aren't Enough

This is where things get frustrating for horse owners. A simple blood test showing antibodies against S. neurona does NOT confirm EPM. Remember, up to half of horses in endemic areas are seropositive. A positive serum test only tells you the horse has been exposed to the parasite at some point. It says nothing about whether the organism is actively causing disease in the CNS.

For a meaningful diagnosis, your veterinarian needs cerebrospinal fluid (CSF), collected via a spinal tap performed under sedation and local anesthesia. The two primary diagnostic tests are:

SAG-ELISA (Surface Antigen ELISA): This test detects antibodies against specific surface antigens (SAG 1, 5, and 6) of S. neurona in the CSF. It's widely available through several diagnostic laboratories and can be run on paired serum and CSF samples to calculate a ratio. A high CSF-to-serum ratio suggests intrathecal antibody production, meaning the horse's CNS is actively fighting the parasite rather than just reflecting systemic exposure.

Western Blot: An older but still used test that detects antibodies against S. neurona proteins in CSF. It provides a positive or negative result and was the gold standard before the SAG-ELISA became available.

No test is perfect. False negatives occur, especially early in disease before the horse has mounted a significant intrathecal antibody response. False positives can result from blood contamination of the CSF sample during collection. Your veterinarian will interpret results alongside clinical signs, neurological exam findings, and response to treatment.

Advanced imaging like MRI can sometimes reveal CNS lesions consistent with EPM but is rarely used in practice due to cost, limited availability of equine MRI, and the requirement for general anesthesia for brain imaging.

Treatment: Ponazuril, Diclazuril, and the Long Road Back

Two FDA-approved treatments currently exist for EPM in horses, and both are antiprotozoal agents that target S. neurona directly:

Ponazuril (Marquis): Administered as an oral paste at 5 mg/kg once daily for 28 days. Ponazuril is a triazine-based antiprotozoal that kills the organism by disrupting its mitochondrial function. It achieves good CNS penetration, which is crucial since the parasite is hiding behind the blood-brain barrier. This has been the most widely used treatment since its FDA approval.

Diclazuril (Protazil): Given as a top-dressed pellet at 1 mg/kg daily for 28 days. Diclazuril belongs to the same drug class and works through a similar mechanism. Some clinicians prefer it for ease of administration since it mixes with feed rather than requiring paste dosing.

An older treatment protocol using a combination of sulfadiazine, pyrimethamine, and folic acid (to counteract the anti-folate effects) was standard before the newer drugs arrived. Some veterinarians still use this protocol, particularly in cost-sensitive situations, though it requires 90-120 days of treatment and carries more side effect potential.

Beyond antiprotozoal drugs, many veterinarians add anti-inflammatory therapy during the initial treatment phase. Flunixin meglumine or phenylbutazone can reduce CNS inflammation, while some clinicians use DMSO or short courses of corticosteroids (carefully, given the immune implications) to manage acute swelling around lesion sites.

Immune support is increasingly part of the conversation. Levamisole, a dewormer with immunostimulatory properties, has been used off-label alongside antiprotozoal treatment with some anecdotal success. Vitamin E supplementation at elevated doses (5,000-10,000 IU daily) is commonly recommended as a neuroprotective antioxidant.

Prognosis: Honest Numbers

Let's be straight about expectations. Roughly 60-70% of horses treated for EPM show measurable improvement. Of those, perhaps 25% return to their previous level of performance. Some horses improve one or two neurological grades but retain residual deficits that limit athletic use. A smaller percentage fail to respond or continue to deteriorate despite treatment.

Factors that predict better outcomes include:

• Mild neurological signs at the time treatment starts (grade 1-2 ataxia)
• Short duration of symptoms before diagnosis
• Young horses with presumably more neural plasticity
• Absence of severe muscle atrophy

Relapse is a real concern. Studies report relapse rates of 10-20% within the first year after treatment, often triggered by stressful events. Some horses require a second course of treatment or long-term maintenance protocols.

Prevention: Keeping Opossums Away From Feed

There is currently no commercially available vaccine for EPM, so prevention centers on reducing exposure to S. neurona sporocysts. Practical strategies include:

• Store grain and hay in sealed containers or buildings that exclude wildlife
• Keep feed rooms closed and opossum-proof (they're surprisingly good climbers)
• Remove fallen fruit, pet food, and garbage that attract opossums to the barn area
• Use covered water troughs rather than open ponds or streams
• Trap and relocate opossums humanely from the immediate barn environment
• Minimize stress during transport, competition, and management changes

Some horse owners in high-risk areas use low-dose daily ponazuril as a preventative during peak stress periods (shipping, show season), though this is an off-label use and not universally endorsed.

Frequently Asked Questions

Explore More

Deepen your understanding of equine neuroanatomy with our interactive spinal cord model, or explore the full equine anatomy to see how the nervous system connects to every other body system.

Sources

• AAEP. "Equine Protozoal Myeloencephalitis." American Association of Equine Practitioners Clinical Guidelines.
• Reed, S.M., et al. "Equine Protozoal Myeloencephalitis: An Updated Consensus Statement." Journal of Veterinary Internal Medicine, 2016.
• UC Davis Center for Equine Health. "EPM: Equine Protozoal Myeloencephalitis." University of California, Davis.
• Dubey, J.P., et al. "Sarcocystis neurona and Equine Protozoal Myeloencephalitis." Veterinary Parasitology, 2015.
• Merck Veterinary Manual. "Equine Protozoal Myeloencephalitis."